Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 10/20 | 1.00 |
| ▸ | HTR3A | P46098 | 4/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | HTR5A | P47898 | 1/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norcisapride SCHEMBL593405 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Norcisapride SCHEMBL3319911 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Norcisapride SCHEMBL3317329 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Norcisapride SCHEMBL734363 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Ticalopride SCHEMBL17208 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| SCHEMBL9790000 | 0.96 | HTR4 (0.92) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| SCHEMBL9789990 | 0.96 | HTR4 (0.92) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| SCHEMBL9789995 | 0.96 | HTR4 (0.92) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Ticalopride SCHEMBL6847230 | 0.92 | HTR4 (0.85) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Water SCHEMBL9721747 | 0.89 | HTR4 (0.80) | HTR4HTR3AHTR3EHTR3BHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629466-B2 | Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080076927-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7326787-B2 | Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders | ARYX THERAPEUTICS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070078265-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | ARYX THERAPEUTICS (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007028073-A2 | SYNTHETIC METHODS AND INTERMEDIATES FOR STEREOISOMERIC COMPOUNDS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARYX THERAPEUTICS, INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076927-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR4 193/4885HTR3A 543/4885HTR3E 806/4885 |
| US-20080085915-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | CCKBR, HRH2, GRPR | HTR4 71/4885HTR3A 282/4885HTR3E 394/4885 |
| US-20090137810-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR4 193/4885HTR3A 543/4885HTR3E 806/4885 |
| US-20070078265-A1 | Synthetic Methods and Intermediates for Stereoisomeric Compounds Useful for the Treatment of Gastrointestinal and Central Nervous System Disorders | CCKBR, GRPR, HRH2 | HTR4 193/4885HTR3A 543/4885HTR3E 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.